Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

SW, Syversen; GL, Goll; KK, Jørgensen; Ø, Sandanger; J, Sexton; IC, Olsen; JE, Gehin; DJ, Warren; MK, Brun; RA, Klaasen; LN, Karlsen; G, Noraberg; C, Zettel; MKA, Ljoså; AJ, Haugen; RJ, Njålla; TJ, Bruun; KA, Seeberg; B, Michelsen; EK, Strand; S, Skorpe; IM, Blomgren; YH, Bragnes; CK, Dotterud; T, Thune; CM, Ystrøm; R, Torp; P, Mielnik; C, Mørk; TK, Kvien; J, Jahnsen; N, Bolstad; EA, Haavardsholm

doi:10.1001/jama.2021.4172

Public

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Shared by NobleBlocks on May 1, 2021 • 12:00 AM UTC

Authors:

Syversen SW

Goll GL

Jørgensen KK

Abstract

<h4>Importance</h4>Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!